Search PubMed⌕ Search

Biomedical subjects

H Zachariae

Publications and source records attributed to H Zachariae.

At least 109 records · Page 6Linked to original sources
PubMed1985

Comparison of oxatomide and clemastine in the treatment of chronic urticaria. A double blind study.

A double-blind trial comparing a new antihistaminic agent (oxatomide) with clemastine was carried out in 30 patients with chronic urticaria. The study included over-all clinical assessment by patient and clinician as well as determination of excretion of 1,4-methylimidazoleacetic acid determined by a reversed-phase ion-pair high-performance liquid chromatographic method. It was found that the effect of oxatomide was equal to that of clemastine.

Adolescent↗
PubMed1985

Topical nitrogen mustard in early mycosis fungoides. A 12-year experience.

A 12-year experience in thirty-three patients suffering from early mycosis fungoides in plaque stage confirms the effectiveness of topical nitrogen mustard therapy. Fourteen patients were in complete remission at the latest time of observation and 7 in partial remission. The probability of freedom from relapse was approximately 50% after 6 and 12 years. Three deaths attributable to mycosis fungoides were recorded. Three patients had to discontinue treatment due to contact dermatitis to nitrogen mustard. Specific precautions were undertaken in order to protect personnel handling the drug. No damaging or toxic effects were observed among staff personnel and no hematological side-effects were observed among the patients. The treatment as a whole was well tolerated.

Administration, Topical↗
PubMed1985

Herpesvirus infection in man.

Herpesviruses which affect man are herpes simplex virus type 1 and type 2, varicella-zoster virus, cytomegalovirus and Epstein-Barr virus. The review deals with the more common clinical manifestations of human herpesvirus infections, which occur ubiquitously in all populations throughout the world. Primary infections most commonly occur in childhood. It is a characteristic feature of herpesvirus that they generally remain in a latent form after clearance of the primary infection. The overall majority of clinical problems are related to activated latent infections, viz. recurrent lesions of herpes simplex, herpes zoster with remaining neuralgia in older patients, and in particular herpesvirus infections and reactivation in immunodeficient individuals. Herpes infection during pregnancy may result in severe generalised infection of the newborn. A possible relationship between herpesvirus and cancer, especially between herpesvirus type 2 and cervical cancer and between Epstein-Barr virus and Burkitt's lymphoma are of major interest today.

Adult↗
PubMed1985

[Oral methotrexate therapy: pro and con].

For the patient suffering from severe disabling psoriasis, there is now a choice of three possible therapeutic modalities: PUVA, retinoid, or cystostatics. We have had the most experience with methotrexate, as it has been used to treat psoriasis for more than 30 years. For this reason, there is also extensive experience with regard to the risk benefit ratio for this drug. Treatment with methotrexate requires normal kidney function, liver, and bone marrow function. Pregnancy is an absolute contraindication. Methotrexate is hepatotoxic. Fibrosis and cirrhosis are not uncommon when the cumulative dosage exceeds 1.5 g; methotrexate-induced liver cirrhosis is not, however, a rapidly progressing disease. Treatment with methotrexate requires regular laboratory control, and experience to date also indicates that liver biopsy specimens should be taken during treatment.

Administration, Oral↗
PubMed1985

Topical nitrogen mustard in mycosis fungoides.

A twelve-year experience in thirty-three patients suffering from early mycosis fungoides in the plaque stage confirmed the effectiveness of topical nitrogen mustard (chlormethine) therapy. Fourteen patients were in complete remission at the latest time of observation and seven in partial remission. The probability of freedom from relapse was approximately 50% after 6 and 12 years. Three deaths attributable to mycosis fungoides were recorded. Another three patients had to discontinue treatment due to contact dermatitis to nitrogen mustard. Specific precautions were undertaken in order to protect personnel handling the drug. No damaging or toxic effects were observed among staff and no haematological side-effects were observed among the patients. The treatment as a whole was well tolerated.

Administration, Topical↗
PubMed1984

Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis.

Monocyte antibody-dependent cell-mediated cytotoxicity (ADCC) was compared to intrinsic cyclic-adenosine-monophosphate (cAMP) levels in 14 patients with systemic sclerosis. Depressed monocyte cytotoxicity was observed. Elevated cAMP levels (2-5 times) in resting monocytes were found in 5 patients; the rest had normal cAMP values. Monocyte ADCC was inversely correlated to cellular cAMP content (r = -0.6659, P less than 0.02). Scleroderma patients with high basal cAMP levels showed impaired responses to beta-adrenergic stimulation but not to prostaglandin E (PGE1) and histamine. Patients with normal basal cAMP levels showed no defect in beta-adrenergic responses. No close correlation between monocyte abnormality and clinical state was found.

Adult↗
PubMed1984

Histologic changes in the liver during etretinate treatment.

Histologic changes in the liver were evaluated in thirty-two patients with different dyskeratotic dermatoses treated with etretinate (Tigason) during an average of 24.9 months. Fatty infiltration, nuclear variability, periportal inflammation, focal necrosis, fibrosis, and cholestasis were estimated. The usual dose was 50-75 mg/day, with reduction according to efficacy and side effects. No statistically significant differences were found between a control group of thirty-five liver biopsies from psoriasis patients who had not received systemic therapy and biopsies from the patients treated with etretinate. Among the thirty-two etretinate-treated patients, six had two serial biopsies, and eight had pretreatment biopsies. No significant changes appeared during therapy.

Adolescent↗
PubMed1984

Establishment of T and B cell lines from patients with mycosis fungoides.

Eighteen patients with mycosis fungoides were studied in order to establish cell lines that might be associated with the human T cell leukaemia-lymphoma virus (HTLV). Three T cell lines were established, two from affected skin and one from a lymph node showing dermatopathic lymphadenopathy. The T cells expressed OKT3 and OKT4 antigens. They temporarily expressed an HTLV p19-like antigen in up to 5% of the cells during culture. None of our patients had lymphocytosis or abnormal lymphocytes, except one patient with Sézary's syndrome. We could not establish T cell lines from peripheral blood, but five B lymphoblastoid cell lines were obtained, all positive for the Epstein-Barr virus nuclear antigen. Our finding that T cell lines can be established from skin biopsies and lymph nodes of patients with mycosis fungoides, but not from the blood, supports the concept of a malignant T lymphocyte primarily localized in the skin. The temporary expression of HTLV p19 antigen may indicate the presence of retrovirus, but further studies are needed.

Adult↗
PubMed1984

Progressive generalized perforating folliculitis.

A case is presented of a 52-year-old female exhibiting a severe progressive generalized perforating folliculitis accompanied by widespread erythroderma, follicular hyperkeratosis, keratoderma of palms and soles, alopecia of scalp and eyebrows, and nail changes. The disease seemed completely resistant to steroids, adrenocorticotropin, PUVA, cytostatic drugs, and aromatic retinoids. This type of skin reaction does not seem to have been described in the dermatologic literature.

Dermatitis, Exfoliative↗
PubMed1983

Methotrexate in psoriatic arthritis: a retrospective study.

The response of psoriatic arthritis to methotrexate was evaluated retrospectively in 59 consecutive patients. Initially almost all received 15 mg weekly. When clinical improvement occurred, the dose was gradually reduced. In 7 patients methotrexate had to be discontinued within a year due to adverse reactions. The remaining 52 patients were treated from 1 to 11 years, median 3 years. Among these a modest improvement was seen in 21, while in 22 the signs of inflammatory joint disease almost disappeared. The favourable response was related to the short duration of arthritis, but unrelated to the severity of the disease.

Adolescent↗
PubMed1983

Results of lymphography in early mycosis fungoides.

Lymphography was performed in 28 patients with mycosis fungoides. In 22 of the patients, the investigation took place prior to 2 months after the diagnosis was established, and in 7 of these lymphography was made before the histological verification of mycosis fungoides was possible. Five patients with widespread, persistent and severe atopic dermatitis served as controls. Eighteen patients with mycosis fungoides (64%) had abnormal lymphograms, while all 5 controls had normal lymphograms. Abnormal findings were diagnosed in 12 of 22 patients at the earliest time possible during the course of their disease and even found in 5 of 7 patients who only had premycotic lesions at the time of investigation. These results may have some bearing on therapy, suggesting that systemic treatment could possibly be introduced at a far earlier disease stage than is the custom at present.

Dermatitis, Atopic↗
PubMed1983

Long-term oral treatment of two pronounced ichthyotic conditions: lamellar ichthyosis and epidermolytic hyperkeratosis with the aromatic retinoid, Tigason (RO 10-9359).

Five patients suffering from lamellar ichthyosis and 3 from epidermolytic hyperkeratosis (previously called non-bullous and bullous congenital ichthyosiform erythroderma) were treated from 11 to 52 months with the synthetic aromatic retinoid Tigason (RO 10-9359). In all cases of lamellar ichthyosis the results were judged as good to excellent, while none of the patients with epidermolytic hyperkeratosis gave more than a slight response. The reason for the poorer results in the latter condition was that effective therapeutic dosages in relation to ichthyosis invariably produced increased blistering. These and other side effects such as cheilitis, mild dryness of mucous membranes, slight hair loss, and pruritus, in no case necessitated discontinuation of the drug.

Administration, Oral↗
PubMed1983

Bestatin therapy of patients with atopic dermatitis.

Ten adult patients with severe atopic dermatitis were treated for three months with estatin, which is a metabolite of Streptomyces olivoreticuli. Bestatin has been shown to increase tumor resistance in mice, augment a variety of immune responses and to reduce the level of IgE in non-atopic healthy persons. During bestatin therapy we were not able to see any clinical change of the atopic dermatitis. No influence was found on the concentration of IgE in serum and the number of eosinophils in blood. The percentage of T lymphocytes and the Con A-induced suppressor cell activity was not changed. (Received June 18, 1983.)

Adjuvants, Immunologic↗